Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
By Peter Yim
WHO updated “Therapeutics and COVID-19” on March 31, 2021 to include a recommendation on ivermectin. The recommendation was:
“We recommend not to use ivermectin in patients with COVID-19 except in the context of a clinical trial.”
The recommendation was made by the Guideline Development Group; 63 members consisting of “content experts, clinicians, patients, ethicists and methodologists”.
WHO explained that a vote on the recommendation was not necessary:
“While a priori voting rules informed procedures if the panel failed to reach consensus, these procedures proved unnecessary for this recommendation.”
- Was there an “a priori” system in place for deciding when and how to abandon the “a priori” voting rules?
- How was consensus determined?
- Is it too late to take a vote?
WHO explained how they reached their “transparent and trustworthy recommendations”. They need to understand that bypassing a vote on the recommendation is the opposite of transparent and trustworthy.